ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential fo...

Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant s...

ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigation...

At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 monthsClinica...

At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 monthsClinica...

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of...

Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company de...

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price tar...